Exagen (NASDAQ:XGN) Given Buy Rating at BTIG Research

BTIG Research reissued their buy rating on shares of Exagen (NASDAQ:XGN) in a research note published on Wednesday,Benzinga reports. The firm currently has a $9.00 price objective on the stock.

A number of other brokerages have also recently weighed in on XGN. Canaccord Genuity Group lifted their price target on shares of Exagen from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, October 19th. Weiss Ratings restated a “sell (e+)” rating on shares of Exagen in a research report on Wednesday, November 4th. B. Riley Financial assumed coverage on shares of Exagen in a research report on Friday, September 11th. They issued a “buy” rating and a $12.00 price objective for the company. Finally, TD Cowen raised their price objective on Exagen from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $9.88.

Exagen Stock Down 4.4%

Exagen stock opened at $5.03 on Wednesday. The company’s 50 day simple moving average is $7.84 and its 200 day simple moving average is $5.13. Exagen has a fifty-two week low of $2.59 and a fifty-two week high of $9.73. The firm has a market capitalization of $121.85 million, a price-to-earnings ratio of -6.71 and a beta of 2.25. The company has a debt-to-equity ratio of 1.96, a current ratio of 3.18 and a quick ratio of 3.18.

Exagen (NASDAQ:XGN) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). Exagen had a negative net margin of 25.14% and a negative return on equity of 123.63%. The firm had revenue of $18.42 million for the quarter, compared to analyst estimates of $18.34 million. As a group, sell-side analysts anticipate that Exagen will post -0.69 EPS for the current year.

Insider Activity at Exagen

In other Exagen news, CEO John Aballi sold 34,294 shares of the firm’s stock in a transaction that occurred on Friday, October 16th. The shares were sold at an average price of $7.87, for a total transaction of $269,893.78. Following the sale, the chief executive officer directly owned 805,540 shares in the company, valued at approximately $6,339,599.80. This trade represents a 4.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Jorey Chernett purchased 7,085 shares of the business’s stock in a transaction on Tuesday, November 10th. The stock was bought at an average cost of $5.26 per share, for a total transaction of $37,267.10. Following the purchase, the insider owned 2,625,625 shares of the company’s stock, valued at approximately $13,810,787.50. This represents a 0.27% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 29,585 shares of company stock worth $195,682 over the last 90 days. Corporate insiders own 10.40% of the company’s stock.

Institutional Investors Weigh In On Exagen

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. GSA Capital Partners LLP acquired a new position in Exagen in the 2nd quarter worth $998,000. Flputnam Investment Management Co. bought a new position in Exagen during the 2nd quarter worth about $1,343,000. Man Group plc bought a new position in Exagen during the 2nd quarter worth about $778,000. BlackRock Inc. acquired a new stake in shares of Exagen in the 2nd quarter valued at about $663,000. Finally, FourWorld Capital Management LLC raised its stake in shares of Exagen by 61.2% in the 1st quarter. FourWorld Capital Management LLC now owns 439,950 shares of the company’s stock valued at $1,320,000 after purchasing an additional 166,950 shares during the period. 75.25% of the stock is currently owned by institutional investors and hedge funds.

Exagen News Roundup

Investors following XGN have been watching these news items:

• Positive Sentiment: Q3 revenue increased 7% year over year to $18.4 million, slightly ahead of estimates. For the first nine months, revenue rose 11%, net loss narrowed 12%, and adjusted EBITDA loss improved by more than 30%. Exagen Q3 results
• Positive Sentiment: Exagen reiterated its 2026 revenue outlook of $72 million to $75 million and remains on track to launch its myositis offering in early 2027. A major shareholder’s recent purchases also exceeded his reported sale in the cited transactions, a modest supportive signal. Insider transaction report
• Negative Sentiment: Q3 adjusted loss of $0.25 per share missed analyst expectations of roughly $0.18–$0.19. Operating expenses increased and the operating loss widened to $4.4 million from $3.1 million a year earlier; cash also fell to $28.1 million from $35.7 million a year earlier. These results highlight continued losses and cash-use concerns despite revenue growth. Q3 earnings report

About Exagen

Exagen Inc. is a commercial-stage diagnostic company focused on improving the diagnosis and management of autoimmune and rheumatic diseases. The company develops and commercializes blood tests that help physicians identify autoimmune disease, distinguish among related conditions and monitor disease activity over time. Its principal product family is AVISE, which includes the AVISE CTD and AVISE Lupus tests, as well as monitoring and specialty tests used in the evaluation of systemic lupus erythematosus and other connective-tissue diseases.